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ABSTRACT 
Research findings have suggested vitamin D enhances innate immunity in 
humans. Vitamin D deficiency among pregnant women is common, especially 
among women of darker skin. Studies have positively correlated newborn cord 25-
hydroxyvitamin D (25(OH)D) with maternal serum 25(OH)D concentration during 
pregnancy. To our knowledge, no studies have addressed the associations between 
maternal serum 25(OH)D levels during pregnancy and incidence of infection in 
infants.  
The aim of this study was to assess the relationship between maternal 
vitamin D status during pregnancy and incidence of infections in infants during the 
first six and twelve months of life. The number and type of medically-diagnosed 
illnesses and infections of 220 infants were collected, and the associations between 
maternal 25(OH)D concentrations and incidence of illness, total infections, and 
specific infection types (respiratory; skin; eye, ear, nose and throat (EENT); and 
others) were examined. Significant negative correlations were found between 
maternal 25(OH)D concentrations and  the incidence of illness (p= 0.022), 
infection(p=0.033), EENT (p=0.043), and skin infections (p=0.021) during the first six 
months, but not during the first 12 months. 
Ethnic differences in this relationship was also examined in infants of African-
American (AA) mothers (n=69) and in those who were not African-American (n=151) 
because we were aware that AA mothers had a higher incidence of vitamin D 
deficiency (plasma 25(OH)D < 50 nmol/L; 84.1% vs. 37.1%) and lower mean plasma 
25(OH)D (35.20 ± 22.74 vs. 63.30 ± 31.96 nmol/L). Infants of AA mothers were more 
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likely than other women to have at least one incidence of any illness (p=0.013) and 
skin infection (p=0.007) during the first six months of life. 
 In infants of non-AA mothers, significant negative correlations were found 
between maternal 25(OH)D concentrations and incidences of skin (p=0.025) and 
EENT (p=0.026) at six months in the first six months of life. The relative risk for 
being diagnosed with at least one EENT and one skin infection with increasing 
25(OH) concentrations trended lower in the first twelve months, but did not reach 
statistical significance.  
Results suggest low maternal vitamin D status during pregnancy increases 
the risk of infection, in particular, the risk of skin and EENT infections in young 
infants. Few AA women had normal vitamin D status (4.3%), compared to women of 
other ethnic groups (26.5%), which could be one reason why their infants had more 
overall illnesses, infections, and skin infections during the first six month of life. 
Clinical trials to improve maternal vitamin D status during pregnancy could 
determine if there is a causal relationship between maternal vitamin D status and 
infant illness from infection, but caution should be taken since high concentrations of 
maternal 25(OH)D may be a risk factor for infant asthma.  
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Chapter 1 
INTRODUCTION 
Vitamin D is well-known for its role in bone metabolism (1). A new area of 
research arose after the discovery of vitamin D receptors in human peripheral 
mononuclear leukocytes and in lymphocytes B and T (2). Vitamin D modulates 
immune function by suppressing adaptive immunity and stimulating innate 
immunity (3, 4). The active form of vitamin D [1, 25(OH)2 D], promotes innate 
immune function by inducing the expression of the  human cathelicidin 
antimicrobial peptide (CAMP) gene (5). In activated macrophages, Toll-like 
receptors mediate up-regulation of the vitamin D receptor gene and the vitamin 
D-α1-hydroxylase gene, to increase 1,25(OH)2D (6). Evidence on the role of 
vitamin D in modulating innate immunity is the basis for research on the role of 
vitamin D in infection. 
Vitamin D deficiency is a pandemic with an estimated 1 billion individuals 
believed to be vitamin D deficient or insufficient (7). US Data from NHANES 
2001-2006 indicate vitamin D deficiency occurs in 42% of non-pregnant women 
of child-bearing age and in 33% of pregnant women (8). In a cohort of 299 
pregnant women in Kansas City metropolitan area, 86% of African American 
women, 56% of Hispanic women, and 35% of Caucasian women were found to 
be vitamin D deficient (25(OH)D < 50 nmol/L) (9). Maternal serum 25(OH)D 
during pregnancy is a significant determinant of the newborn’s vitamin D status at 
birth. The newborn’s cord 25(OH)D correlates positively with maternal serum 
25(OH)D levels during pregnancy; reported correlations range from 0.79 to 0.898 
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(10-14). Reported cord blood concentration ranges from two-thirds to equal to 
maternal concentration (3, 10-14). There is very limited evidence for an increase 
in infection during infancy related to lower intrauterine vitamin D status. Camargo 
et al. (15) report an inverse association between cord-blood 25(OH)D and risk of 
respiratory infection by 3 months of age in 922 infants studied in New Zealand. A 
small study (n=25) of infants admitted to the intensive care unit for acute lower 
respiratory tract infections found significantly lower mean serum 25(OH)D 
compared to age-matched healthy controls (n=15) (16). No studies were located 
addressing the associations maternal plasma 25(OH)D levels during pregnancy 
and incidence illness, including infection, in infants. 
Statement of Purpose: 
The primary purpose of this study was to compare vitamin D status in 
pregnancy with the incidence of infections in their infants during the first six and 
twelve months of life. The women were from the Kansas City metropolitan area 
and participated in a clinical trial with infant follow-up that included 
documentation of illness from periodic interviews and medical records. We 
compared infant infections overall and by body system, e.g. respiratory and skin, 
with maternal vitamin D status. We independently compared illness in African-
American and  women of other ethnic groups, because the former group had a 
much higher incidence of vitamin D deficiency. The relationship between illness 
and maternal vitamin D status was also explored in infants of African-American 
women and of all other women.  
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Research Questions: 
Primary research question:  
Is there an association between maternal plasma 25(OH) vitamin D levels 
during pregnancy and the number of total medically-diagnosed infections 
experienced by that woman’s infant during the  first six and twelve months of life? 
Secondary research questions: 
1) Are specific types of infant infections (respiratory; skin; eye, ear, nose and 
throat infections) related to maternal vitamin D status during pregnancy? 
2) Do infants of African-American and non- African American women have a 
similar relationship between maternal vitamin D status and either total or 
specific types of infections? 
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Chapter 2 
LITERATURE REVIEW 
INTRODUCTION 
Vitamin D is well-known for its role in bone metabolism (1). The discovery 
of vitamin D receptors in non-bone tissues led to a new area of research on other 
functions of vitamin D. These functions can be described based on their general 
regulation effect on hormone secretion, immune function, or cellular proliferation 
and differentiation. In this review, the prevalence and causes of vitamin D 
deficiency, as well as the role of vitamin D in immune function are discussed. 
Focus is made on the evidence for vitamin D deficiency in pregnancy and the 
relationship between maternal vitamin D status during pregnancy and infant 
vitamin D status and immune function. 
ASSESSMENT OF VITAMIN D STATUS 
Vitamin D status is determined based on plasma 25-hydroxyvitamin D3 
concentration (25(OH)D) (17). There is a debate on the optimal 25(OH)D 
concentration for defining deficiency.  Common values indicating vitamin D 
deficiency and insufficiency are plasma concentrations of 25(OH)D less than  50 
nmol/L and between 50- 75 nmol/L respectively. A plasma 25(OH)D of 75 -250 
nmol/L indicates sufficient vitamin D status (1, 18-20). The Institute of Medicine 
(IOM) uses more conservative concentrations and divides vitamin D status into 
four categories based on plasma 25(OH)D concentration: risk of deficiency (<30 
nmol/L), risk of inadequacy (30–49 nmol/L), sufficiency (50–125 nmol/L), and  
possibly toxic (>125 nmol/L) (21). The less conservative values for vitamin D 
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status are based on the assumption that optimal serum 25(OH)D is the level  at 
which parathyroid hormone concentration does not rise (22) and fractional 
calcium absorption plateaus at a serum 25(OH)D concentration of 75nmol/L (23, 
24). A serum 25(OH)D concentration greater than 375 nmol/L indicates vitamin D 
intoxication (17). 
VITAMIN D DEFICIENCY  
VITAMIN D DEFICIENCY IN THE UNITED STATES OF AMERICA 
Unless otherwise indicated, vitamin D status is defined based the 
25(OH)D concentration categories used prior to the release of the recent IOM 
report on calcium and vitamin D dietary reference intakes (21). These 
concentrations are used because only one published study on vitamin D status in 
the US used the new IOM levels (25). Vitamin D deficiency is a pandemic, with 
an estimated 1 billion individuals being vitamin D deficient or insufficient (7). In 
the US, vitamin D deficiency has a different prevalence among different age 
groups. Of 380 infants and toddlers from a Boston urban clinic, 12.1% were 
vitamin D deficient (26). On the other hand, the prevalence among children and 
adolescents in the US ranges from 30 to 52% (27-30). Older adults in the US are 
at high risk of vitamin D deficiency, with a prevalence ranging from 40 to 100% 
(7). 
Vitamin D deficiency is more prevalent among African Americans (31). In 
southern states, 53 to76% of non-Hispanic blacks are vitamin D insufficient, 
depending on age and gender. Prevalence in non-Hispanic white is 8 to 33% 
(32). Based on recent IOM categories, non-Hispanic Black Americans had a 
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significantly higher prevalence of Vitamin D deficiency (32%) as compared to 3% 
in non-Hispanic whites (25). Lower 25(OH)D levels in African Americans are 
attributed mainly to the reduction in vitamin D synthesis with greater skin 
pigmentation (34). Melanin acts as a sunscreen by competing with skin 7-
dehyrocholesterol for ultraviolet B (UVB) radiation. The higher the melanin 
content in skin, the lower is the biosynthesis of previtamin D3 (33). Another 
contributing factor is lower dietary intake of vitamin D among African Americans 
(34). Estimates of daily intake of vitamin D from food and dietary supplements 
are significantly lower in African American (6.9 ± 0.3 µg/d) than in Whites (8.4 ± 
0.4 µg/d ) based on analysis of NHANES data from 1999–2000 (34). 
VITAMIN D DEFICIENCY WORLDWIDE  
Vitamin D deficiency is prevalent in other parts of the world. One 
explanation for the geographical difference of vitamin D deficiency is the effect of 
latitude on vitamin D biosynthesis. Less UVB photons penetrate the ozone layer 
from October to March at latitudes above 37 degrees north and below 37 
degrees south (35). Mean 25(OH)D levels are lower in people living in these 
areas; e.g., Boston (42 ºN) , northern Spain (43.5 ºN), northern France (49ºN), 
and Edmonton (52 ºN), compared to mean 25(OH)D levels in areas of latitudes 
between 37 º south and 37º north (30, 36, 37). Vitamin D biosynthesis may occur 
during the entire year in areas between 37º south and 37º north, such as in 
Puerto Rico (18 ºN), Los Angeles (24 ºN), and Buenos Aires (34 ºS) (35). 
Individuals living in countries where culture imposes the covering of the body and 
face have increased risk of vitamin D deficiency (38, 39). Few studies have 
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addressed the effect of clothing on vitamin D status in the Middle East. Although 
the studies had small sample sizes, results suggest vitamin D deficiency is more 
common among veiled Kuwaiti and Lebanese women as compared to women 
without veils (38, 40). The observation of serum levels lower than 5 ng/ml (12.4 
nmol/L) in most veiled women (38) suggests a major contribution of the veil to 
severe hypovitaminosis D. Prevalence of vitamin D deficiency in African 
countries is variable due to differences in latitude, climate, dress, and food 
availability across the continent (41). Dark skin pigmentation is a common risk 
factor for vitamin D deficiency among Africans regardless of the country (39). 
Melanin acts as a sunscreen by competing with skin 7-dehyrocholesterol for UVB 
radiations. Therefore, the higher the melanin content in darker skin, the lower is 
the biosynthesis of previtamin D3 (33).  
MATERNAL VITAMIN D STATUS DURING PREGNANCY  
Suboptimal vitamin D status is common among pregnant women in the 
US. Data from NHANES 2001-2006 indicate vitamin D deficiency occurs in 42% 
of non-pregnant women of child-bearing age and in 33% of pregnant women (8). 
Using the recent IOM-determined vitamin D categories for the same NHANES 
2001-2006 data (21), 7% of pregnant or lactating women would be considered 
deficient, compared to 12% of women who are not yet pregnant or lactating (25). 
Bodnar et al. (42) reported the prevalence of vitamin D deficiency (25(OH)D < 
37.5 nmol/L) and insufficiency (25(OH)D 37.5–80 nmol/L) in 200 white and 200 
black pregnant women residing in Pittsburg, Pennsylvania. Vitamin D deficiency 
and insufficiency at delivery occurred in 29.2% and 54.1% respectively in African 
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American women, compared to 5% and 42.1% in white women. The study did 
not report vitamin D status in the overall sample, regardless of race. Forty-one 
percent of pregnant women (n=494) in South Carolina were vitamin D deficient 
(25(OH) D < 50nmol/L), and an additional 41% were insufficient (25(OH)D 50-80 
nmol/L) during early pregnancy (43). Hamilton et al. (44) reported a similar 
distribution of vitamin D status of pregnant women in South Carolina (n= 559) 
with 48% of women being deficient and 37% insufficient. In a cohort of 299 
pregnant women in Kansas City metropolitan area, 86% of African American 
women, 56% of Hispanic women, and 35% of Caucasian women were found to 
be vitamin D deficient (25(OH)D < 50 nmol/L) (9). 
THE RELATION BETWEEN MATERNAL VITAMIN D STATUS DURING 
PREGNANCY AND VITAMIN D STATUS OF THE NEWBORN  
Maternal plasma 25(OH)D concentration during pregnancy is significantly 
correlated with cord blood plasma 25(OH)D (45), with cord blood concentration 
being from two-thirds to equal maternal concentrations (3, 10-13, 39). A positive 
correlation exists between maternal and infant plasma 25(OH)D concentrations 
within 72 hours after birth (45). The positive correlation may be explained by the 
ability of serum 25(OH) D to cross the placenta. In contrast, maternal serum 1, 
25(OH)2D does not cross the placenta and does not contribute to the newborn’s 
serum 1, 25(OH)2D levels (46). Breast-fed infants rely on 25(OH)D stored during 
gestation to meet their requirements during the first few months of life, because 
breast milk is a poor source of vitamin D (46). Maternal vitamin D deficiency is a 
significant risk factor for infant vitamin D deficiency (45, 47). Mothers of rachitic 
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infants have a higher prevalence of vitamin D deficiency compared to mothers of 
nonrachitic infants (48, 49).   
VITAMIN D AS MODULATOR OF THE IMMUNE SYSTEM  
Vitamin D plays a role in modulating both adaptive and innate immune 
functions. These roles were investigated after the discovery of vitamin D 
receptors in human peripheral mononuclear leukocytes and in B and T 
lymphocytes (2). The adaptive immune response is specific to the type of antigen 
presented to lymphocytes by macrophages and dendritic cells. It involves the 
release of cytokines and antibodies by B and T lymphocytes. The active form of 
vitamin D (1, 25(OH)2D) suppresses adaptive immunity by different mechanisms. 
Vitamin D inhibits the maturation of dendritic cells, reducing their ability to 
present antigens to lymphocytes T4. At the same time, 1, 25(OH)2D has opposite  
effects on CD4 cell differentiation. Vitamin D inhibits CD4 cell differentiation to 
Th1 and Th17 cells and stimulates CD4 cell differentiation to Th2 and Treg cells 
(50, 51). This shift in CD4 cell differentiation is postulated to be the basis for a 
potential role of vitamin D in preventing and treating autoimmune diseases. 
Administration of 1, 25(OH)2D and its analogues in non-obese diabetic mice 
prevent systemic lupus erythematosus, inflammatory arthritis, inflammatory 
bowel disease, and autoimmune diabetes. Analogs of 1,25(OH)2D3 also treat 
type 1 diabetes and allergic encephalomyelitis, an experimental model for 
multiple sclerosis in mice (52). Observational studies have associated vitamin D 
deficiency and low vitamin D intake in humans with increased risk of Crohn’s 
disease, type I diabetes, rheumatoid arthritis, and multiple sclerosis (53-56). 
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Randomized controlled trials testing the hypothesis that vitamin D can prevent 
autoimmune diseases are needed to prove the causality of vitamin D deficiency. 
On the other hand, suppression of the adaptive immune response by 1, 
25(OH)2D  could reduce the body’s ability to fight infectious agents; however, 
there is currently not published evidence for such an effect from published 
observational or interventional studies. 
Innate immunity is characterized by non-specific and quick responses 
against pathogens, as the primary protective barrier between the body and the 
external environment. Epithelial cells, monocytes, phagocytes, and macrophages 
have transmembrane pathogen recognition receptors, called Toll-like receptors 
(TLRs). Once activated, innate immunity cells release reactive oxygen and 
nitrogen intermediates and antimicrobial peptides, including cathelicidin. The 
active form of vitamin D promotes innate immune function by inducing the 
expression of the human cathelicidin antimicrobial peptide (CAMP) gene (5).  
Active vitamin D (1, 25(OH)2D) increases in activated macrophages by TLRs-
mediated up-regulation of the vitamin D receptor and the vitamin D-α1-
hydroxylase genes (6). Evidence that vitamin D modulates innate immunity led to 
research focused on the role of vitamin D in infection. 
VITAMIN D AND INFANT INFECTION  
Camargo et al. (15) reported an inverse association between cord-blood 
25(OH)D and risk of respiratory infection in the first 3 months of life. They 
reported increased incidence of wheezing at 15 months, 3 years and 5 years in 
the same cohort of 922 infants. Neonates with cord-blood 25(OH)D  less than 50 
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nmol/L have a sixfold higher risk of respiratory syncytial viral infection in the first 
year of life compared to those with 25(OH)D concentrations greater than 75 
nmol/L (57). Newborns admitted to the intensive care unit for acute lower 
respiratory tract infections have significantly lower mean serum 25(OH)D than 
healthy controls (16).  
Maternal vitamin D status during pregnancy is postulated to influence 
immunity of her offspring but more studies focused on its effect on asthma than 
on infections per se.  Asthma is a disease of the adaptive immune system. New 
cell-culture studies suggest that asthma is a syndrome manifested due to an 
interaction between both innate and acquired immune systems (58). Although 
evidence supports a protective role of maternal vitamin D intake against infant 
wheezing (59-61), associations between maternal vitamin D intake and infant 
asthma are inconsistent. Devreux et al (60) did not find a significant association 
between maternal vitamin D intake from the diet or through dietary supplements 
and asthma in children (n=1751) at 5 years (OR=0.99 per quintile of energy-
adjusted vitamin D intake, p=0.98). Maternal vitamin D intake from food was 
related to risk of asthma in Finnish 5- year-old children susceptible for type 1 
diabetes (n=1669) (62). Maternal serum 25(OH)D greater than 30 ng/ml was 
associated with a 5-fold risk of asthma in children at 9 years of age compared to 
children with maternal 25(OH)D levels less than 12 ng/ml (63). In the same 
study, children exposed to maternal 25(OH)D levels greater than 30 ng/mL 
during late pregnancy were more likely as well to be diagnosed with atopic 
eczema at 9 months of age (63). The severity of viral lower respiratory tract 
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illnesses in infants during their first year of life was not associated with maternal 
vitamin D levels at time of illness (64). However, the relevance of a potential 
association is not clear. The relationship between maternal serum 25(OH)D 
levels during pregnancy and incidence of infection in infants has not been 
investigated to our knowledge. 
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Chapter 3 
METHODS 
Overview: 
This study used data collected from the Kansas University DHA Outcomes 
Study (KUDOS). The primary goal of the KUDOS study was to determine 
whether prenatal docosahexanoic (DHA) supplementation could improve 
pregnancy outcomes (eg. gestational length, birth weight, development of 
preeclampsia, gestational diabetes, etc) and infant cognitive development. The 
study design was a randomized double-blind, placebo-controlled clinical trial 
(registered as NCT00266825 at www.clinicaltrials.gov). The purpose of the 
present subordinate study was to assess the relationship between vitamin D 
status in a cohort of pregnant women from the Kansas City metropolitan area, 
and the total number of infections in their infants during the first year of life.  The 
study also addressed if a specific type of infant infection is affected by maternal 
vitamin D status. The study investigated if infants of women of African descent 
have the same or different relationship between maternal vitamin D status and 
infection, compared to infants of non African American descent. 
 Sample  
Two hundred and twenty infants of mothers who participated in the 
KUDOS trial are the sample. The KUDOS study included 350 women who met 
the following inclusion criteria: aged 16-35, BMI less than 40, pregnant with a 
single fetus at 8th to 20th week of gestation, and provided informed written 
consent. Women who had any serious illness, high blood pressure, or diabetes 
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were excluded from the study. Until the day of delivery, subjects consumed either 
a daily 600 mg DHA capsule or a placebo vegetable oil capsule. After delivery, 
infants and their caregiver visited the study center for follow-up at the following 
periods of the infant’s age: at 6 weeks and 4,6,9,10,12, and 18 months of age. 
For this vitamin D study, infants were included if they were born full-term (≥ 37 
weeks of gestation), had completed their first year of life, their maternal plasma 
25(OH) vitamin D concentrations were known, and medical records for the first 
year of life were available. Infants with serious illnesses (eg. cyctic fibrosis, HIV) 
that could compromise their susceptibility to infection were excluded from the 
study.  
Setting  
Women in the KUDOS trial were recruited between April 2006 and 
November 2009. The recruitment process took place at clinics at the University of 
Kansas Medical Center (Kansas City, Kansas), St. Luke’s Hospital (Kansas City, 
Missouri), and Truman Medical Center (Kansas City,Missouri ) and by email 
contact to KUMC employees. Some women were recruited through word of 
mouth.  All women delivered their babies in hospitals in Kansas City metropolitan 
area, with the last infant born in May 2009. Infants returned with their caregiver to 
the study center at the University of Kansas Medical Center for follow-up visits at 
specific internals during infancy: at 6 weeks and 4, 6, 9, 10, 12, and 18 months.  
Ethics 
The Human Subjects Committee at the University of Kansas Medical 
Center reviewed and approved the research protocols, amendments, informed 
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consent, and procedures of the KUDOS trial.  This subordinate study uses blood 
measurements of nutrients and other assessments approved under the study. 
Data from medical records were authorized for the KUDOS trial and approved for 
release from infants’ legal caregivers (Appendix A). This study is covered under 
the KUDOS HSC approval (HSC #10186). All participants provided informed 
consent at enrollment. 
Procedures and materials: 
The study design is a retrospective Cohort study. Maternal blood samples 
were collected at time of pregnant women enrollment, separated into plasma and 
red blood cell samples, and stored at minus 80 degrees Celsius. Plasma 
25(OH)D concentrations were analyzed using an enzyme-linked immunosorbent 
assay (ELISA) kit (Immundiagnostik AG, Bensheim, Germany) by the Kansas 
Intellectual and Developmental Disabilities Research Center (K-IDDRC) 
laboratory, as part of a previous study (9). The procedure for 25(OH)D assay is 
described in Appendix B.  
Maternal race, number of pack years of smoking, and infant feeding 
(breastfeeding, formula-feeding, or both) during the first four months were self-
reported by the mothers. Maternal gestational age at enrollment was determined 
from medical records. Maternal red blood cell phospholipid DHA concentrations 
at delivery were analyzed by gas liquid chromatography, after extraction, 
phospholipid separation by thin layer chromatography, and transmethylation with 
BF3-methanal. Maternal DHA concentrations were analyzed in this study to 
control for potential confounding effects of maternal DHA status during 
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pregnancy on study outcomes. Docosanoids derived from DHA are proposed to 
be anti-inflammatory agents, and may therefore modulate infant’s immunity (65). 
Incidence, duration, and type of infections were recorded from medical records 
and cross-referenced with caregiver reports solicited during all follow-up visits to 
the study center. When the infant reached 1 year of age, medical records were 
requested from every clinic or hospital that the infant had attended, and faxed to 
the study center. During follow-up visits to the study center, the caregiver was 
asked about any infant illness, medication use, hospital/clinic visits, and 
corresponding treatment since the previous follow-up visit. Appendix C shows the 
adverse event log used during caregiver interviews. Any serious adverse event 
reported by the care giver (defined as any incidence of illness, hospitalization, or 
death) resulted in an immediate request for the infant’s medical record and a 
report to the HSC. Infections reported by the parents and not confirmed in the 
medical records were not included in this study. Data on adverse events 
extracted from medical records were coded by type of illness and body system 
affected. Coding was within eleven main categories, as indicated in Appendix D: 
body as a whole; cardiovascular; eyes, ears, nose, throat (EENT); endocrine; 
gastrointestinal; metabolic and nutrition; musculoskeletal; nervous; respiratory; 
skin; and urogenital. For this study, the KUDOS database was used to capture 
the number and the kind of infection (s) each infant had in the first 12 months of 
life. Illness denoted any medically- diagnosed condition reported in the infant’s 
medical record, whether it was an infection or not.  Infections were derived from 
four categories: EENT, respiratory, skin; and all others (Appendix E).  
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The KUDOS database included needed data of demographic 
characteristics of the mothers, maternal delivery 25(OH) D concentrations and 
the number and types of medically-diagnosed illnesses and infections. 
Statistical analysis: 
Measurements of continuous variables are reported as mean ± standard 
deviation at 95% Confidence Intervals; number of cases and percentage (%) 
from total were used to report measurements of categorical variables. 
Differences in maternal baseline characteristics between AA and all other 
mothers were analyzed using independent sample t-test for continuous variables 
and Pearson Chi-Square for categorical variables. Plasma 25(OH)D distribution 
between the two racial groups did not meet the assumption of equal variances; 
therefore, Welch-Satterthwaite t-test was used to analyze differences in mean 
25(OH)D concentrations. Prevalence of vitamin D deficiency, insufficiency, and 
sufficiency among African-American women and all other women are reported as 
percentage of total group (%). Comparison of prevalence within each vitamin D 
category was analyzed using Pearson Chi square test.   
The relationships between maternal baseline characteristics for the two 
groups of women were analyzed using Spearman’s correlation test for 
continuous not-normally distributed variables (maternal DHA levels, maternal 
25(OH)D levels, and pack years of smoking).  Univariate analysis of variance 
was used to assess differences in 25(OH)D levels across infant feeding groups. 
Illness and infection types were not normally distributed. Therefore, non- 
parametric Spearman correlation test was used to analyze the correlations 
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between 25(OH)D and infection types. Relative Risk (RR) was calculated to 
assess the risk of infections at different vitamin D categories. Significant 
differences in RR were assessed by Pearson Chi square test. Statistical 
significance was considered for two-tailed P value<0.05 for descriptive analysis 
(baseline maternal characteristics and incidence of infant illnesses) and one-
tailed P value<0.05 for correlation tests.  SPPS version 18 was used for 
statistical analysis. 
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Chapter 4 
RESULTS 
Maternal baseline characteristics 
Two hundred and twenty women participated in this study; 69 (31.4%) 
were African American (AA) women and 151 (68.6%) were not. That group 
included 135 Caucasians, 12 Hispanics, and 3 others. Baseline maternal 
characteristics are summarized in Table 1.  
TABLE 1 
Baseline maternal characteristics 
 
Maternal characteristics All study 
subjects 
(n=220) 
AA* women 
(n=69) 
Other  women 
(n=151) 
AA 
compared to 
others  
(P Value) 
Gestational age at 
enrollment (weeks) 
 
Maternal DHA 
concentrations (weight % 
from red blood cell 
phospholipids)  
 
Plasma 25(OH) vitamin D 
concentrations (nmol/L) 
 
Vitamin D status, n (%)  
    Deficient 
14.6 ± 3.49 
 
 
6.18 ± 2.27 
 
 
 
 
54.41 ±32.10 
 
 
 
114 (51.8) 
15.23 ± 3.45 
 
 
5.42 ± 1.66 
 
 
 
 
35.20 ± 22.74 
 
 
 
58 (84.10) 
14.30 ± 3.49 
 
 
6.52 ± 2.43
d 
 
 
 
 
63.20± 31.96 
 
 
 
56 (37.1)
 
0.059 
a 
 
 
<0.001
a 
 
 
 
 
<0.001
b 
 
 
<0.001
c 
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    Insufficient 
    Sufficient 
 
Infant feeding during 1
st
 4 
months of life, n (%) 
    Exclusive breastfeeding 
    Exclusive formula feeding 
    Both   
 
Smoked before pregnancy, 
n (%) 
63 (28.6) 
43 (19.5) 
 
 
 
53 (24.1) 
69 (31.4) 
95 (43.2) 
 
95 ( 43.18) 
 
8 (11.60) 
3 (4.30) 
 
 
 
25 (36.76) 
5 (7.35) 
38 (55.88) 
 
30 (43.48) 
 
55 (36.4) 
40 (26.5) 
 
 
 
28 (18.79)
e 
64 (42.95) 
57 (38.26) 
 
65 (43.05) 
 
 
 
 
<0.001
c 
 
 
 
 
0.952
a 
 
* AA : African American Women  
a
 P value calculated from independent sample t-test 
b 
P value calculated from Welch-Satterthwaite t-test 
c
 P value calculated from Pearson Chi-squared test 
d
217 subjects analyzed; excluded 3 subjects (2 African Americans and 1 non-African America) 
with unknown DHA concentrations.  
e
 217 subjects analyzed; excluded 3 subjects (1 African American and 2 non-African Americans) 
with unknown infant feeding type 
 
Women were enrolled in the study during their first or second trimester of 
gestation, with a mean gestational age of 14.6 ± 3.49 weeks. Mean maternal 
25(OH)D concentration at enrollment was 54.41 ±32.10 nmol/L, with 51.8% of 
the subjects being vitamin D deficient, 28.6% insufficient, and 19.5% sufficient. 
Univariate analysis shows that women who exclusively breastfeed their infants 
had significantly lower plasma 25(OH) D than other women (p=0.001). Plasma 
25(OH) D was significantly correlated with red blood cell phospholipid DHA 
concentrations (r=0.232; p=0.001), but not with pack years of smoking.   
Incidence of infant illness and infection 
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Table 2 and 3 summarize the number and percentage of infants with at 
least one medically-diagnosed illness or infection, during the first six and twelve 
months of life, respectively. During the first six months of life, 83.6% of all infants 
had at least one medically-diagnosed illness. By the time all infants reached 
twelve months of age, 95% of them had at least one illness. Diagnosis with at 
least one respiratory infection was the most prevalent diagnosis, in approximately 
42% of all infants at six months and 62% at twelve months.   
TABLE 2 
Infants with at least one incidence of a medically-diagnosed illness or infection during 
the first six months of life   
Illness or infection 
category, n (%) 
All infants 
(n=220) 
Infants of AA* 
mothers (n=69) 
Infants of other 
mothers 
(n=151) 
P Value** 
Any illness  184 (83.6) 64 (92.96) 120 (79.47) 0.013 
Any Infection 144 (65.5) 54 (78.27) 90 (59.60) 0.007 
EENT Infection  67 (30.5) 26 (37.68) 41 (27.15) 0.115 
Respiratory 
Infection 
94 (42.7) 29 (42.09) 64 (42.38) 0.887 
Skin Infection 46 (20.9) 22 (31.88) 24 (15.89) 0.007 
Other Infections  26 (11.8) 10 (14.49) 16 (10.60) 0.406 
*AA: African American 
**P value calculated from Pearson Chi-square test for comparison of illness or infection 
incidence between infants of AA mothers and other mothers 
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TABLE 3 
 Infants with at least one incidence of a medically-diagnosed illness or infection during 
the first twelve months of life   
Illness or infection 
category, n (%) 
All infants 
(n=220) 
Infants of AA* 
mothers (n=69) 
Infants of non-
AA mothers 
(n=151) 
P Value** 
Any illness  208 (95.00) 66 (95.65) 142 (94.04) 0.756 
Any Infection 192 (87.70) 60 (89.96) 132 (84.42) 0.827 
EENT Infection  128 (58.4) 36 (52.17) 92 (60.93) 0.201 
Respiratory 
Infection 
137 (62.6) 43 (62.32) 94 (62.25) 0.961 
Skin Infection 87 (39.7) 32 (46.38) 55 (36.42) 0.173 
Other Infections  54 (24.7) 18 (26.09) 36 (23.84) 0.739 
*AA: African American 
**P value calculated from Pearson Chi-square test for comparison illness or infection 
incidence between infants of AA mothers and other mothers 
 
Tables 4 and 5 summarize the mean number of medically-diagnosed 
illnesses and infections during the first six and twelve months of life respectively.  
TABLE 4 
 Mean ± standard deviation of medically-diagnosed illness or infections during the first 
six months of life   
Illness or infection 
category, n (%) 
All infants 
(n=220) 
Infants of AA* 
mothers (n=69) 
Infants of other 
mothers 
(n=151) 
P Value** 
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Any illness  2.55 ± 2.16 3.10 ± 1.97 2.30 ± 2.20 0.008 
Any Infection 1.4 ± 1.49 1.68 ± 1.49  1.26 ± 1.47 0.056 
EENT Infection  0.43 ± 0.90 0.61 ± 1.26 0.35 ± 0.65 0.113 
Respiratory 
Infection 
0.64 ± 0.91 0.61 ± 0.83 0.66 ± 0.96 
 
0.710 
Skin Infection 0.24 ± 0.51 0.39 ± 0.65 0.17 ± 0.41 0.011 
Other Infections  0.13 ± 0.38 0.19 ± 0.50 0.11 ± 0.31 0.204  
*AA: African American 
**P value calculated from independent sample t-test for comparison between infants of 
AA mothers and other mothers 
 
TABLE 5.  
Mean ± standard deviation of medically-diagnosed illness or infections during the first 
twelve months of life   
Illness or infection 
category, n (%) 
All infants  
(n=220) 
Infants of AA* 
mothers (n=69) 
Infants of non-
AA mothers 
(n=151) 
P Value** 
Any illness  4.99 ± 3.67 5.62 ± 3.89 4.69 ± 3.54 0.094 
Any Infection 3.30 ± 2.73 3.46 ± 2.78 3.22 ± 2.71 0.546 
EENT Infection  1.05 ± 1.24 1.07 ± 1.44 1.05 ± 1.15 0.896 
Respiratory 
Infection 
1.27 ± 1.40 1.26 ± 1.31 1.27 ± 1.44 0.950 
Skin Infection 0.64 ± 0.95 0.77 ± 0.97 0.58 ± 0.94 0.181 
Other Infections  0.34 ± 0.66 0.38 ± 0.73 0.32 ± 0.63  0.577 
*AA: African American 
**P value calculated from independent sample t-test for comparison between infants of 
AA mothers and other mothers 
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Correlations between maternal 25(OH)D concentrations and infant 
outcomes  
During the first six months of life, significant negative correlations were 
found between maternal 25(OH)D concentrations and  the following infant 
outcomes: incidence of illness(p= 0.022), infection(p=0.033), EENT (p=0.043), 
and skin infections (p=0.021). At twelve months, none of the correlations reached 
statistical significance (Table 6). A scatter plot of the number of infections 
diagnosed during the first six months versus maternal 25(OH)D is represented in 
figure 2. The fit-line of the scatter plot shows a decreasing trend for number of 
infections with increasing maternal 25(OH)D levels.  
TABLE 6 
Univariate analysis of associations between maternal plasma 25 (OH) D concentrations 
and number of medically-diagnosed infant illnesses and infections during Six and Twelve 
Months of Life 1 
Illness/infection type Correlation *  P value 
Any illness 
               At 6 months 
               At 12 months 
Any infection  
               At 6 months 
               At 12 months 
EENT infections             
               At 6 months 
               At 12 months 
 
−0.136 
−0.053 
 
−0.125 
−0.023 
 
−0.116 
0.008 
 
 
 
0.022 
0.220 
 
0.033 
0.365 
 
0.043 
0.453 
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Respiratory infections 
               At 6 months 
               At 12 months 
Skin infections 
              At 6 months 
              At 12 months 
Other infections 
             At 6 months 
             At 12 months 
 
 0.010 
0.009 
 
−0.137 
−0.064 
 
−0.097 
−0.060 
 
0.444 
0.450 
 
0.021 
0.172 
 
0.076 
0.189 
1 n= 220 
*Correlation was determined using Spearman rank correlation coefficient (1-tailed)  
 
 
 FIGURE 1. Scatter plot of the relation between maternal plasma 25(OH)D concentration 
and number of infant infections during the first six months of life  
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Relative risk for being medically-diagnosed with at least one illness or 
infection 
Table 7 compares the risk of being diagnosed with at least one illness or 
infection at a particular maternal vitamin D status, to the risk of diagnosis at any 
other maternal vitamin D status.  Differences in relative risk (RR) between 
vitamin D categories did not reach statistical significant at six and twelve months.  
However, there was a decreasing trend for RR for EENT and skin infections 
during the first six months of life. RR for EENT infections decreased from 1.22 in 
the deficient group (<50 nmol/L) to 0.64 in the sufficient group (>75 nmol/L) at six 
months. RR for skin infections decreased from 1.74 in the deficient group to 0.62 
in the sufficient group at six months.  
 
TABLE 7 
 Relative risk for medically-diagnosed infant illnesses and infections at six and twelve 
months of age according to maternal plasma 25(OH) vitamin D categories  
 25(OH)D concentrations, nmol/L    
<50 50-75 >75  P value* 
Any illness 
               At 6 months 
               At 12 months 
Any infection  
               At 6 months 
               At 12 months 
EENT infections             
 
1.04 
1.00 
 
1.16 
1.00 
 
 
0.96 
0.98 
 
0.86 
0.94 
 
 
1.00 
1.04 
 
0.95 
1.08 
 
 
 
 
0.776 
0.635 
 
0.284 
0.392 
 
27 
 
               At 6 months 
               At 12 months 
Respiratory infections 
               At 6 months 
               At 12 months 
Skin infections 
              At 6 months 
              At 12 months 
Other infections 
             At 6 months 
             At 12 months 
1.22 
0.94 
 
0.97 
0.96 
 
1.74 
1.22 
 
1.49 
1.20 
1.06 
0.93 
 
1.00 
1.10 
 
0.69 
0.88 
 
0.75 
1.02 
0.64 
1.19 
 
1.04 
0.96 
 
0.62 
0.85 
 
0.75 
0.70 
0.311 
0.406 
 
0.972 
0.725 
 
0.120 
0.517 
 
0.572 
0.582 
*P values were calculated from Pearson Chi Square test  
 
Racial differences in maternal baseline characteristics  
No significant difference in gestational age between AA women and other 
women was found at enrollment. AA women had significantly lower mean red 
blood cell phospholipid DHA concentrations and plasma 25(OH)D  levels 
(p<0.001). AA women were more likely to breastfeed their infants exclusively 
during their first four months of life than others (p<0.001). The percentage of 
women who smoked before pregnancy was almost similar in both groups (Table 
1).  
Racial differences in maternal vitamin D status and its relationship with 
infant outcomes 
Figure 2 shows the percent distribution of vitamin D status by race. The 
differences in percentages within each vitamin D category were statistically 
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significant (p<0.001). AA women had a significantly higher prevalence of vitamin 
D deficiency, in 84.06% of AA women compared to 37.09% of other women. Only 
4.35% of AA women in our study were vitamin D deficient, compared to 26.49% 
of other women. 
 
FIGURE 2. Maternal vitamin D status distribution (%) by race. * P<0.001 
When comparing incidences of illness in infants by maternal race, we 
found that infants of AA mothers were more likely to have at least one incidence 
of any illness (p=0.013), any infection (p=0.007), and skin infection (p=0.007) 
during the first six months of life (Table 2). This difference was not statistically 
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significant at twelve months (Table 3). Compared to infants of other mothers, 
infants of AA mothers had significantly higher number of illnesses (p=0.008) and 
skin infections (p=0.001) during the first six months of life (Table 4). At twelve 
months, there was no significant difference in mean number of illness and 
infections between the two groups (Table 5). 
Correlations between maternal 25(OH)D concentration and infant illnesses 
within each racial group separately are shown in tables 7 and 8. Correlations in 
infants of AA mothers were not significant at six or twelve months of age (Table 
7). At six months but not at 12 months, in infants of all other women, incidences 
of skin (p=0.025) and EENT (p=0.026) were significantly correlated with maternal 
25(OH)D concentrations (Table 8).  
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1 n= 69 
*Correlation was determined using Spearman rank correlation coefficient (1-
tailed) 
TABLE 8 
Univariate analysis of associations between maternal plasma 25 (OH)vitamin D and 
number of medically-diagnosed illnesses and infections at 6 and 12 months of age in 
infants of African American mothers 1 
Illness/infection type Correlation *  P value 
Any illness 
               At 6 months 
               At 12 months 
Any infection  
               At 6 months 
               At 12 months 
EENT infections             
               At 6 months 
               At 12 months 
Respiratory infections 
               At 6 months 
               At 12 months 
Skin infections 
              At 6 months 
              At 12 months 
Other infections 
             At 6 months 
             At 12 months 
 
0.057 
0.084 
 
-0.002 
0.038 
 
0.108 
-0.039 
 
-0.082 
-0.039 
 
0.119 
0.161 
 
-0.125 
0.061 
 
 
 
0.320 
0.246 
 
0.493 
0.379 
 
0.188 
0.374 
 
0.253 
0.374 
 
0.166 
0.093 
 
0.153 
0.308 
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TABLE 9 
 Univariate analysis of associations between maternal plasma 25 (OH)vitamin D and 
number of medically-diagnosed illnesses and infections at 6 and 12 months of age in 
infants of non-African American mothers  1 
Illness/infection type Correlation *  P value 
Any illness 
               At 6 months 
               At 12 months 
Any infection  
               At 6 months 
               At 12 months 
EENT infections             
               At 6 months 
               At 12 months 
Respiratory infections 
               At 6 months 
               At 12 months 
Skin infections 
              At 6 months 
              At 12 months 
Other infections 
             At 6 months 
             At 12 months 
 
-0.064 
-0.028 
 
-0.103 
0.012 
 
-0.158 
0.014 
 
0.001 
0.028 
 
-0.159 
-0.110 
 
-0.093 
-0.097 
  
0.216 
0.369 
 
0.105 
0.440 
 
0.026 
0.432 
 
0.497 
0.366 
 
0.025 
0.090 
 
0.127 
0.118 
1 n= 151 
*Correlation was determined using Spearman rank correlation coefficient (1 
tailed)  
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Chapter 5 
DISCUSSION 
Maternal vitamin D status during pregnancy 
Suboptimal vitamin D status was common among pregnant women in our 
study. Mean maternal 25(OH)D concentration was 54.41 ±32.10 nmol/L, with 
51.8% of the subjects being vitamin D deficient, 28.6%being insufficient, and 
19.5% being sufficient. This distribution aligns with results from previous studies 
on vitamin D status in the pregnant American women (8, 9, 42-44, 66). The high 
prevalence of vitamin D deficiency  may be attributed to reduced vitamin D 
biosynthesis caused by the latitude of Kansas City (39° 6' N) (35). Located above 
37°N, less UVB penetrates the ozone layer between October and March, causing 
a significant decrease in vitamin D biosynthesis (35). Low vitamin D intake might 
have had a minor effect on vitamin D deficiency, because the contribution of 
vitamin D intake to vitamin D status is minimal (34). The discrepancy in vitamin D 
status between women of different skin color has been previously reported in the 
literature (25, 31-34, 39, 41). National data on vitamin D from 2001-2006 show 
that white women were less likely to be “at risk of deficiency” than black women, 
after adjusting for age and season (25). As anticipated, we found that the highest 
prevalence of vitamin D deficiency in our study was among AA’s, with a 
percentage of 84.1% as compared to 37.1% in other women.  
  We found women who exclusively breastfed their infants during the first 4 
months of life were all vitamin D deficient (<50 nmol/L). They had significantly 
lower plasma 25(OH) D than other women in the study (41.71±4.30 vs. 58.47 
33 
 
±2.45 nmol/L). While the risk of low vitamin D status early in pregnancy is clearly 
not caused by breastfeeding, it does raise concern for high risk of infant 
hypovitaminosis D, especially as milk vitamin D reflects maternal vitamin D 
status.. If infants are not supplemented with vitamin D or adequately exposed to 
sun light, vitamin D content of deficient mothers alone would not be enough to 
meet their vitamin D requirements (46, 68). We do not have sufficient data on 
vitamin D supplementation in our infants to assess the consistency and 
adequacy of supplementation during the breastfeeding period.  
Relationship between maternal 25(OH) D concentration and infant 
outcomes 
The first year of life is critical for the infant’s immune system development 
(71). Prenatal events can affect immune responses at birth, and acquisition of 
immune competence increases from birth to two years of age, with increased 
antigen exposure (71). We postulated that low maternal plasma 25(OH)D would 
be a “prenatal event” potentially altering the infant’s immune function during the 
first year of life. Respiratory infection was the most prevalent diagnosis in infants 
of our study with approximately 42% of infants at six months and 62% at twelve 
months having at least one respiratory infection. Respiratory distress is among 
the top ten causes for infant death in the United States (72); however, we found 
no studies with which to compare this prevalence.  
We found a significant negative correlation between maternal 25(OH)D 
concentration and  incidence of illness and  infection, specifically EENT and skin 
infection, during the first six months of life. Our study is the first to examine the 
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association between maternal 25(OH)D concentrations during pregnancy and 
incidence of infection in the offspring during infancy. Previous studies examined 
the effects of maternal vitamin D intake during pregnancy and offspring immune 
outcomes, mainly asthma (59, 60, 62). Maternal 25 (OH) concentrations above 
75 nmol/L during pregnancy were associated with infant asthma and atopic 
eczema (63). 
Relative risk for being medically-diagnosed with at least one illness or 
infection 
We were unable to detect statistically significant differences in relative risk 
(RR) for being diagnosed with at least one illness or infection among vitamin D 
categories. This study was a sub-study from the KUDOS trial, and consequently 
our study was not powered. Lack of adequate power and small sample size of 
mothers in the vitamin D sufficient group may have contributed to the insignificant 
RR outcome. We found a decreasing trend for RR for EENT and skin infections 
during the first six months of life. The Center for Disease Control (CDC) 
considers 3 or more ear infections annually as one of the determinants of health 
status (67). Our finding of reduced RR (RR=0.64) for EENT infections in infants 
of vitamin D sufficient mothers suggest that a sufficient vitamin D level during 
pregnancy is potentially a good determinant for infant health, based on CDC 
criteria.  
Racial differences in the relationship between maternal 25(OH)D and infant 
outcomes 
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We also examined the relationship between maternal 25(OH)D 
concentration and infant infections, in each racial group separately. Our results 
suggest that during the first six months of life, infants of non-AA mothers have 
higher incidences of skin and EENT infections if their mothers have lower plasma 
25(OH)D concentrations during pregnancy. We did not find a similar correlation 
in infants of AA mothers, but the group was smaller and the vast majority had 
vitamin D insufficiency or deficiency (95.6%).It is possible a similar correlation 
exists in infants of AA women, and this would have been found if our sample 
included a larger number of AA women with a wider range of vitamin D levels. 
This concept is reflected in the scatter plot of the number of infant infections 
versus maternal 25(OH)D concentrations (Fig. 2). Although the fit-line shows a 
negative relationship between the two variables, statistical significance is not 
achieved because few values of high maternal 25(OH)D are plotted in the graph. 
We investigated the likelihood that the difference in infection rates between 
infants of different maternal races may be due to factors other than maternal 
vitamin D levels. We found no significant difference in mean number of infections 
between infants of AA and other mothers, who were vitamin D deficient (data not 
shown). This means that differences in infection rates are less likely to be caused 
by factors other than maternal vitamin D levels (e.g. socioeconomic and 
educational factors).  
Limitations 
In our study, we used maternal 25(OH)D concentrations measured from 
blood samples collected at enrollment. Mean gestational age at enrollment was 
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14.6 ± 3.49 weeks. One limitation is the potential difference in 25(OH)D 
concentrations at enrollment and at delivery. However, Marwaka et al (73) found 
that the prevalence of vitamin D deficiency was not different across the three 
different trimesters. Prevalence of vitamin D deficiency among 48 non-
supplemented pregnant women was reduced from 60 % during the first trimester 
to 48% at the second trimester and reduced by only 1 % at the third trimester 
(74).  
The majority of our AA mothers were vitamin D deficient. Lack of a big 
sample size of AA women in the vitamin D sufficient group reduced our ability to 
evaluate maternal 25(OH)D and infant outcomes in that race. This study was a 
retrospective Cohort study, analyzing data that has already been collected as 
part of the KUDOS trial. Therefore, one limitation is that infant incidences of 
illness and infection were not the primary outcome measures. In our study, we 
only used illnesses that have been medically-diagnosed and excluded adverse 
events only reported by the parents. This would increase the accuracy of our 
dependent variables; however parents might not have reported all the visited 
clinics and hospitals for their infant treatments.  
A potential limitation that was ruled out was an influence of DHA 
supplementation on infant illness and infection.  Long chain fatty acids, especially 
eicosapentanoic acid and DHA, modulate host resistance to infection, mainly by 
modulating eicosanoid and lipid peroxidation pathways (75, 76). We found a 
significant correlation between maternal RBC phospholipid’s DHA and 25(OH)D 
concentrations. However, maternal red blood cell phospholipid DHA 
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concentration at delivery did not modify the relationship between maternal 
vitamin D status and infant infection (data not shown).  
Conclusion and future directions 
This study shows maternal vitamin D status has the potential to modulate 
infant immunity, especially during the first six months of life. This was the first 
study to associate maternal 25(OH) vitamin D levels during pregnancy with infant 
incidence of illness and infections. We found that maternal 25(OH) vitamin D 
concentrations are negatively correlated with incidence of infant illness, skin, and 
EENT infections during the first six months of life. We were unable to detect a 
significant correlation in infants of AA mothers, due to disproportional distribution 
of vitamin D status in our sample. Studies with vitamin D supplementation to 
improve vitamin D status are needed to determine if improving vitamin D status 
can reduce risk of infections during infancy. Randomized controlled trials are 
needed to determine cut-off maternal 25(OH)D levels for minimum risk of infant 
infection development. Long-term translational research is needed to validate 
whether health care policies addressing the correction of maternal vitamin D 
deficiency during pregnancy would reduce infant mortality and illness.  
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Chapter 6 
SUMMARY 
The aim of this study was to assess the relation between maternal vitamin 
D status during pregnancy and incidence of infections in infants during the first 
six and twelve months of life. We collected the number and type of medically-
diagnosed illnesses and infections of 220 infants from the KUDOS trial, and we 
examined the associations between maternal 25(OH)D concentrations and 
incidence of illness, total infections, and specific infection types (respiratory; skin; 
eye, ear, nose and throat, and others). We also examined this relation in infants 
of African American and non-African American mothers separately. 
Mean maternal 25(OH)D concentration at enrollment was 54.41 ±32.10 
nmol/L, with 51.8% of the subjects being vitamin D deficient (plasma 25(OH)D < 
50 nmol/L), 28.6% being insufficient (25(OH)D 50-75 nmol/L), and 19.5% being 
sufficient (25(OH)D > nmol/L). Among African American (AA) mothers (n=69), 
84.1% were vitamin D deficient, and 37.1% of other mothers (n=151) were 
vitamin D deficient. Mean 25(OH)D concentration was significantly lower in AA 
mothers (35.20 ± 22.74 nmol/L) as compared to other mothers (63.30 ± 31.96 
nmol/L) (p<0.001).  Infants of AA mothers were more likely to have at least one 
incidence of any illness (p=0.013), any infection (p=0.007), and skin infection 
(p=0.007) during the first six months of life. Significant negative correlations were 
found between maternal 25(OH)D concentrations and  the incidence of illness(p= 
0.022), infection(p=0.033), EENT (p=0.043), and skin infections (p=0.021) during 
the first six months of life. At twelve months, none of the correlations reached 
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statistical significance. After analyzing these correlations within each racial group 
separately, correlations in infants of AA mothers were no longer significant at six 
or twelve months. In infants of other mothers, significant negative correlations 
were found between maternal 25(OH)D concentrations and incidences of skin 
(p=0.025) and EENT (p=0.026) at six months only. The difference in relative risk 
(RR) of being diagnosed with at least one illness or infection at a different 
maternal vitamin D statuses did not reach statistical significant at six and twelve 
months.  However, there was a decreasing trend for RR for EENT and skin 
infections during the first six months of life. RR for EENT infections decreased 
from 1.22 in the deficient group (<50 nmol/L) to 0.64 in the sufficient group (>75 
nmol/L). RR for skin infections decreased from 1.74 in the deficient group to 0.62 
in the sufficient group at six months.  
This study supported our hypothesis that a negative association exists 
between maternal 25(OH)D concentrations in pregnancy and incidence of 
infection in infants during the first six months of life. A similar relationship was not 
found at twelve months. The study suggested increased incidence and risk of 
total infections, skin and EENT infections in infants of vitamin D deficient mothers 
of non-AA descent. The majority of AA mothers being vitamin D deficient reduced 
the statistical power to detect significant correlations in infants of AA mothers. 
This study did not support our hypothesis that infants of AA descent would have 
a similar association of maternal vitamin D status with incidence of infection. 
Further studies are needed to investigate a causal relationship between low 
vitamin D status during pregnancy and risk of infections during infancy. 
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Randomized controlled trials of large sample size and a wide range of vitamin D 
status distribution in AA and other mothers are needed to validate our result. 
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APPENDIX A 
CONSCENT FORM FOR RELEASE OF MEDICAL RECORDS 
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APPENDIX B 
25(OH)D ASSAY 
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Plasma 25(OH)D assay is performed using an enzyme-linked 
immunosorbent assay (ELISA) kit (Immundiagnostik AG, Bensheim, Germany) 
(77).  
Procedure: 
1) Pipette 30 μL of standards, controls, and plasma samples and place each 
into a labeled 1.5 mL Eppendorf tube.  
2) Add 300 μL of releasing reagent into each tube and vortex briefly. 
3) Incubate the tubes for 1 hour at 37 °C in a water bath or heating block. 
4) Add 600 μL of sample dilution buffer into each tube and vortex briefly. 
5) Pipette 100 μL of the mixture from each tube into 2 designated wells of 
the 96-well microtiter plate. 
6)  Add 150 μL of anti-25(OH)D antibody solution into each well and cover 
the plate. 
7)  Incubate for 18-22 hours at 8-10 °C in the dark. 
8) Aspirate and wash the wells 5 times with 250 μL of diluted wash buffer 
using an 8-channel pipette. Using paper towel, remove the residual wash 
buffer in the wells after the last wash. 
9) Add 200 μL of peroxidase-conjugated antibody solution into each well and 
cover the plate. 
10) Incubate for 1 hour at room temperature while shaking with a horizontal 
microtiter plate shaker. 
11) Repeat step 8. 
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12) Add 200 μL of TMB substrate into each well. 
13) Incubate for 10-15 minutes at room temperature in the dark. 
14) Add 50 μL of ELISA stop solution into each well. 
15) Read the plate using a microtiter plate reader at 450 nm. 
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APPENDIX C 
ADVERSE EVENT LOG SHEET 
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APPENDIX D 
LISTING OF ADVERSE EVENT COLDS BY BODY SYSTEMS 
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APPENDIX E 
LISTING OF ADVERSE EVENT BY GROUPS 
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Listing of Adverse Events by Groups 
EENT Infections Respiratory 
Infections 
Skin Infections Other Infections 
- Bacterial eye 
infection 
- Infectious 
conjunctivitis 
- Eyelid 
Infection 
- Infectious 
rhinitis 
- Infectious 
sinusitis 
- Otitis externa 
- Otitis media 
- Purulent 
rhinitis 
- Staph 
infection in 
eye 
- Thrush   
 
- Bronchiolitis 
- Bronchitis 
- Croup  
- Pneumonia 
- Respiratory 
syncytial virus 
- Strep throat 
- Tonsillitis 
- Upper 
respiratory 
infection 
-  
- Atopic 
dermatitis 
- Bacterial skin 
infection 
- Diaper rash 
- Fungal skin 
infection 
- Impetigo 
- Intertrigo 
- Pruritis  
- Staph skin 
infection 
- Viral skin 
infection 
- Yeast 
infection  
- Acute 
gastroenteritis 
-  Colitis  
- Gastrointestinal 
infection 
- Infectious 
gastroenteritis  
- Necrotizing 
enterocolitis 
- Salmonella in 
stool 
- Stomatitis  
- Meningitis 
- Urinary tract 
infection 
- Vulvitis/vaginitis  
- Sepsis  
- Rule out sepsis 
- Systemic fungal 
infection 
- Fever  
 
*Illness category included all adverse events in Appendix C excluding: accident 
and trauma 
 
